MARKET

PLX

PLX

Protalix Biother
AMEX
1.760
-0.050
-2.76%
Pre Market: 1.730 -0.03 -1.70% 08:00 12/18 EST
OPEN
1.840
PREV CLOSE
1.810
HIGH
1.850
LOW
1.740
VOLUME
182
TURNOVER
0
52 WEEK HIGH
3.100
52 WEEK LOW
1.320
MARKET CAP
141.54M
P/E (TTM)
38.18
1D
5D
1M
3M
1Y
5Y
1D
Protalix, Secarna in agreement to develop rare kidney disorder therapies
Seeking Alpha · 22h ago
Protalix, Secarna Partner To Develop ASO Treatments For Rare Renal Conditions
NASDAQ · 1d ago
Protalix Biotherapeutics Announced A Collaboration With Secarna Pharmaceuticals For The Discovery Of Novel Antisense Oligonucleotide Therapies Against Multiple Targets For Rare Renal Indications, Deal Terms Were Not Disclosed
Benzinga · 1d ago
Protalix Biotherapeutics and Secarna Pharmaceuticals Enter into Collaboration and Option Agreement
PR Newswire · 1d ago
Weekly Report: what happened at PLX last week (1208-1212)?
Weekly Report · 3d ago
Weekly Report: what happened at PLX last week (1201-1205)?
Weekly Report · 12/08 09:39
Weekly Report: what happened at PLX last week (1124-1128)?
Weekly Report · 12/01 09:37
Weekly Report: what happened at PLX last week (1117-1121)?
Weekly Report · 11/24 09:40
More
About PLX
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of uncontrolled gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase) - a chemically modified enzyme to treat uncontrolled gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate. Its product includes Elelyso and Elfabrio. Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease.

Webull offers Protalix Biotherapeutics Inc stock information, including AMEX: PLX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PLX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PLX stock methods without spending real money on the virtual paper trading platform.